The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma.
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer
Michele Del Vecchio
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Honoraria - Bristol-Myers Squibb; MSD; Roche/Genentech
Jacob Schachter
Honoraria - Roche
Claus Garbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche; SOBI
Bart Neyns
No relevant relationships to disclose
Mario Mandala
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Paul Lorigan
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Other Remuneration - Roche
Wilson H Miller
Consultant or Advisory Role - Bristol-Myers Squibb; Roche
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Alexander David Guminski
Consultant or Advisory Role - Specialised Therapeutics
Honoraria - Specialised Therapeutics
Carola Berking
Consultant or Advisory Role - Roche
Honoraria - Roche
Piotr Rutkowski
Consultant or Advisory Role - Novartis
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Paola Queirolo
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Ana Maria Arance
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
Michael Paul Brown
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Lada Mitchell
Employment or Leadership Position - Roche
Maria Luisa Veronese
Employment or Leadership Position - Roche
Christian U. Blank
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Bristol-Myers Squibb